Monday, August 31, 2026
ExploreSearch
Via News
Marketstock

FuboTV Stock Went Up By Over 27% In The Last 21 Sessions

FuboTV Stock Went Up By Over 27% In The Last 21 Sessions

(VIANEWS) - Shares of FuboTV (NYSE: FUBO) rose by a staggering 27.21% in 21 sessions from $1.47 to $1.87 at 17:47 EST on Monday, after four successive sessions in a row of losses. NYSE is sliding 0.04% to $15,318.85, following the last session's downward trend.

About FuboTV

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-2.02.

Volume

Today's last reported volume for FuboTV is 9558192 which is 52.41% below its average volume of 15139000.

More news about FuboTV (FUBO).

Categories

Marketstock

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNYSEMarket SessionNYAThe New York Stock ExchangeStock Price UpFuboTVFUBOPrice UpMarket Session Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com